Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Severe Vincristine-induced Neuropathic Pain in a CYP3A5 Nonexpressor With Reduced CYP3A4/5 Activity: Case Study.

Clinical therapeutics - 1 Jan 2016

Bosilkovska Marija, Ing Lorenzini Kuntheavy, Uppugunduri Chakradhara Rao S, Desmeules Jules, Daali Youssef, Escher Monica

Abstract excerpt

PURPOSE: Peripheral neuropathy is a frequent vincristine-induced adverse effect. Vincristine is a substrate of P-glycoprotein and is metabolized by the cytochrome P-450 (CYP) 3A5 and 3A4 isoforms, with CYP3A5 contributing to 75% of the intrinsic clearance of vincristine. Alterations in the function of these proteins may lead to an increase in vincristine toxicity. CYP3A5 nonexpressor status has been associated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Phytogenic
Share to ATP Binding Cassette Transporter, Subfamily B

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP3A

Share to Microtubule-Associated Proteins

Share to Neuralgia

Share to Pain Measurement

Share to Vincristine

Share to Young Adult

Source

Identifiers

PMID: 26565076
DOI: 10.1016/j.clinthera.2015.10.017

Genes

CEP72
ABCB1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Severe Vincristine-induced Neuropathic Pain in a CYP3A5 Nonexpressor With Reduced CYP3A4/5 Activity: Case Study.PMID 26565076Read ↗

Association of CYP3A5 Expression and Vincristine Neurotoxicity in Pediatric Malignancies in Turkish Population.Semantic proximity Read ↗

Genetic factors influencing the development of vincristine-induced neurotoxicity.Semantic proximity Read ↗

CYP3A5 genotype and its impact on vincristine pharmacokinetics and development of neuropathy in Kenyan children with cancer.Semantic proximity Read ↗

The molecular genetics of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis.Semantic proximity Read ↗

Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia.Semantic proximity Read ↗

Vincristine-Induced Peripheral Neuropathy in Childhood Acute Lymphoblastic Leukemia: Genetic Variation as a Potential Risk FactorSemantic proximity Read ↗

Pharmacogenomics of Vincristine‐Induced Peripheral Neuropathy Implicates Pharmacokinetic and Inherited Neuropathy GenesSemantic proximity Read ↗

Association of CEP72 rs924607 TT Genotype with Vincristine-induced Peripheral Neuropathy Measured by Motor Nerve Conduction Studies.Semantic proximity Read ↗

Whole-Exome Sequencing Reveals Defective CYP3A4 Variants Predictive of Paclitaxel Dose-Limiting NeuropathySemantic proximity Read ↗

Vincristine Disposition and Neurotoxicity Are Unchanged in Humanized CYP3A5 Mice.Semantic proximity Read ↗

The Pharmacogenomics of Vincristine-Induced Neuropathy: On Pins and Needles.Semantic proximity Read ↗

Efficacy and Toxicity of Vincristine and CYP3A5 Genetic Polymorphism in Rhabdomyosarcoma Pediatric Egyptian Patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.